Abstract
Inappropriate PI3K signaling is one of the most frequent occurrences in human cancer and is critical for tumor progression. A variety of genetic mutations and amplifications have been described affecting key components of this pathway, with implications not only for tumorigenesis but also for resistance to targeted agents. Emerging preclinical research has significantly advanced our understanding of the PI3K pathway and its complex downstream signalling, interactions and crosstalk. This knowledge, combined with the limited clinical antitumor activity of mTOR complex 1 inhibitors, has led to the development of rationally designed drugs targeting key elements of this pathway, such as pure PI3K inhibitors (both pan-PI3K and isoform-specific), dual PI3K/ mTOR inhibitors, Akt inhibitors, and mTOR complexes 1 and 2 catalytic site inhibitors. This review will focus primarily on an analysis of newly developed inhibitors of this pathway that have entered clinical trials, and recently registered patents in this field.
Keywords: Cancer, drug development, mTORC1, mTORC2, PI3K, patent, protein kinase B/Akt
Recent Patents on Anti-Cancer Drug Discovery
Title: Recent Developments in Anti-Cancer Agents Targeting PI3K, Akt and mTORC1/2
Volume: 6 Issue: 2
Author(s): Rodrigo Dienstmann, Jordi Rodon, Ben Markman and Josep Tabernero
Affiliation:
Keywords: Cancer, drug development, mTORC1, mTORC2, PI3K, patent, protein kinase B/Akt
Abstract: Inappropriate PI3K signaling is one of the most frequent occurrences in human cancer and is critical for tumor progression. A variety of genetic mutations and amplifications have been described affecting key components of this pathway, with implications not only for tumorigenesis but also for resistance to targeted agents. Emerging preclinical research has significantly advanced our understanding of the PI3K pathway and its complex downstream signalling, interactions and crosstalk. This knowledge, combined with the limited clinical antitumor activity of mTOR complex 1 inhibitors, has led to the development of rationally designed drugs targeting key elements of this pathway, such as pure PI3K inhibitors (both pan-PI3K and isoform-specific), dual PI3K/ mTOR inhibitors, Akt inhibitors, and mTOR complexes 1 and 2 catalytic site inhibitors. This review will focus primarily on an analysis of newly developed inhibitors of this pathway that have entered clinical trials, and recently registered patents in this field.
Export Options
About this article
Cite this article as:
Dienstmann Rodrigo, Rodon Jordi, Markman Ben and Tabernero Josep, Recent Developments in Anti-Cancer Agents Targeting PI3K, Akt and mTORC1/2, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (2) . https://dx.doi.org/10.2174/157489211795328503
DOI https://dx.doi.org/10.2174/157489211795328503 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Disintegrins from Snake Venoms and their Applications in Cancer Research and Therapy
Current Protein & Peptide Science Subject Index To Volume 6
Current Topics in Medicinal Chemistry Stochastic Neighbor Embedding Algorithm and its Application in Molecular Biological Data
Current Bioinformatics Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation
Current Cancer Drug Targets Delirium in Older Patients – A Review
Current Psychiatry Reviews The Ligand Nanoparticle Conjugation Approach for Targeted Cancer Therapy
Current Drug Metabolism Biomarker Diversity, Validation and Clinical Translation: Tenets for Emergent Personalized Medicine Initiatives
Current Pharmacogenomics and Personalized Medicine Regulation of Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor Signaling by Plant Flavonoids
Mini-Reviews in Medicinal Chemistry Pharmacokinetics and Disposition of Various Drug Loaded Biodegradable Poly(Lactide-Co-Glycolide) (PLGA) Nanoparticles
Current Drug Metabolism Overview: Translating Hsp90 Biology into Hsp90 Drugs
Current Cancer Drug Targets Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications
Current Cancer Drug Targets Therapy-Related Changes in the Serum Proteome Patterns of Early Stage Breast Cancer Patients with Different Outcomes
Protein & Peptide Letters Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 2. Structural Analogues and Derivatives
Current Drug Targets Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews Signaling Pathways that Regulate Basal ABC Transporter Activity at the Blood- Brain Barrier
Current Pharmaceutical Design Modified Polysaccharides as Carriers for Biomolecules
Pharmaceutical Nanotechnology Stability Studies on Piroxicam Encapsulated Niosomes
Current Drug Delivery How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments
Current Pharmaceutical Design Regulation of LDLR, Bcl-2 and FASN Expressions by Oxidized Low Density Lipoprotein in Estrogen Receptor Positive Breast Cancer Cells
Current Pharmacogenomics and Personalized Medicine The History, Mechanism and Clinical Use of Oral 5-Fluorouracil Derivative Chemotherapeutic Agents
Current Pharmaceutical Biotechnology